IL13RA2 and glioblastoma: Nonetheless, multiple phase I clinical trials of CAR T cell products have been deployed in glioma, with a specific focus on GBM-specific antigens such as EGFR and EGFRvIII, IL-13Rα2, and B7-H3 [51,52].